75 results
424B5
EYEN
Eyenovia Inc
9 Apr 24
Prospectus supplement for primary offering
7:11pm
from the sale of securities under this prospectus for general corporate purposes, including, but not limited to, clinical trials, research … and development activities, working capital, capital expenditures, acquisitions, should we choose to pursue any, and collaborations. We have not determined
8-K
EX-99.1
EYEN
Eyenovia Inc
13 Nov 23
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
4:15pm
of approximately $(7.3) million, or $(0.21) per share, for the third quarter of 2022.
Research and development expenses totaled approximately $3.6 million … Ended
September 30,
Operating Income
Revenue
Cost of revenue
Gross Profit
Operating Expenses:
Research and development
General and administrative
Total
424B5
jw6dqban
25 Aug 23
Prospectus supplement for primary offering
12:07pm
8-K
EX-99.1
ne0idne2hg9gzckb3
10 Aug 23
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
EX-99.1
gsz yxhj1tzvti
11 May 23
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
4:28pm
8-K
EX-99.1
53457x uvry
30 Mar 23
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
4:16pm
8-K
qb8fcajuhqoso96w
8 Dec 22
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
8:14am
8-K
EX-99.1
jqkmti01ft lemkmo4
8 Dec 22
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
8:14am
8-K
EX-99.1
fq2ld niphh0pzhql
10 Nov 22
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
4:24pm
8-K
EX-99.1
p2iwlf2 0xfn28zebvfq
10 Aug 22
Eyenovia Reports Second Quarter 2022 Financial Results
4:55pm